Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Lytix Biopharma AS does not have enough data to calculate 10-Year RORE %.
Lytix Biopharma AS (OSL:LYTIX) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Lytix Biopharma AS 10-Year RORE % Related Terms
Lytix Biopharma AS 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Lytix Biopharma AS's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:LYTIX vs VRTX, REGN, RVMD: 10-Year RORE % Comparison
For the Biotechnology subindustry, Lytix Biopharma AS's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lytix Biopharma AS 10-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Lytix Biopharma AS's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Lytix Biopharma AS (OSL:LYTIX) has a 10-Year RORE % of 0.00 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Lytix Biopharma AS and its competitors. According to the industry distribution chart, Lytix Biopharma AS ranks #999999 out of 616 companies in the Biotechnology industry.
Is Lytix Biopharma AS's 10-Year RORE % too high?
Lytix Biopharma AS's current 10-Year RORE % is 0.00. Based on the distribution chart, Lytix Biopharma AS ranks #999999 out of 616 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lytix Biopharma AS has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's 10-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lytix Biopharma AS ranks #999999 out of 616 companies for 10-Year RORE %. This places Lytix Biopharma AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Biotechnology company?
A good 10-Year RORE % depends on the Biotechnology industry context. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current 10-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Based on GuruFocus' analysis, Lytix Biopharma AS (OSL:LYTIX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.17, compared to a current price of kr8.10 — trading 4664.7% above its estimated fair value. The current 10-Year RORE % is 0.00. Lytix Biopharma AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Lytix Biopharma AS (OSL:LYTIX), the current 10-Year RORE % is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lytix Biopharma AS (OSL:LYTIX) Overvalued in 2026?
Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued.
The current stock price of kr8.10 is trading 4664.7% above its estimated GF Value™ of kr0.17.
GuruFocus considers Lytix Biopharma AS to be Significantly Overvalued.
Key valuation signals for OSL:LYTIX:
10-Year RORE %: 0.00
GF Value™: kr0.17 vs. price of kr8.10 (4664.7% above fair value)
No single metric tells the full story. See the OSL:LYTIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
28GF Score
Get the complete analysis for OSL:LYTIX
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:LYTIX has been successfully added to your 
